|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0290 - 0.0327|
|52 Week Range||0.0170 - 0.1919|
|Beta (3Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”). Abattis is also pleased to announce that it will be relaunching its Company Newsletter (the “Newsletter”), which has been designed to complement the Company’s continuous disclosure, and provide cannabis industry highlights as they pertain to the Company.
VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that its wholly-owned subsidiary, 1185277 B.C. Ltd. (the "Acquisition Subsidiary"), has entered into a share purchase agreement (the "Agreement") to acquire (the "Acquisition") Pro Natura BV ("Pro Natura"), a privately held nutraceutical company based in Oisterwijk, Netherlands. Pro Natura has over 30 years of operations and sales experience in Europe, with over 100 products that have been marketed to both long-term repeat customers and new large groups of distributors. Pro Natura has been supported by a seasoned management team that still includes its original founder and has historically boasted €10M+ in per annum sales.
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.About Abattis Bioceuticals Corp.Abattis is positioned to be ...
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) provides the following update on the Company’s recent trading halt and upcoming conference call with Company management that was previously set for March 1, 2019. Further to the Company’s news release dated February 18, 2019, trading of the Company’s common shares continues to be halted on the Canadian Securities Exchange until the Company files its financial statements for the year ended September 30, 2018 (the “Financials”).
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide the following update on the Company’s recent trading halt and upcoming conference call with Company management set for March 1, 2019. On February 4, 2019, the trading of the Company’s common shares was halted due to the Company’s failure to file its year-end financial statements within the 90 day filing deadline required under National Instrument 51-102 – Continuous Disclosure Requirements. The Company is still undergoing its year-end financial statement audit and believes it will have them filed in the coming week.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission (“BCSC”), issued on November 26, 2018 (the “Order”), has not been extended against Abattis. “Abattis is very happy with the BCSC’s decision to remove the Company from the Order such that Abattis can continue to focus its efforts on revenue generation and building shareholder value” stated Rob Abenante, President and CEO of Abattis.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that, further to its new release dated December 7, 2018, the Company has entered into a definitive share exchange agreement (the “Agreement”) with 1157016 B.C. Ltd., dba NutriVida, a private arm’s length company incorporated in the Province of British Columbia (“NutriVida”), pursuant to which the Company will acquire 100% of the issued and outstanding common shares of NutriVida (the “Acquisition”). In consideration for the Acquisition, and on closing thereof, the Company will issue an aggregate of 58,823,529 common shares (each, a “Share”) in the capital of Abattis, pro rata, to the NutriVida shareholders at a deemed price of $0.085 per Share and make a cash payment of $250,000 as provided in the Agreement.
Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce the launch of its new website and provide an operational update. Abattis has recently unveiled its new marketing and branding materials, developed in conjunction with media company Canada One Communications Inc. (“Canada One”). Marketing materials include an updated website, corporate presentation and conference materials all highlighting Abattis’ new brand imagery (“new marketing materials”).
VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Abattis Bioceuticals Corp (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce its first proprietary product, Comfort, which has been produced through wholly owned subsidiary Vergence Naturals ("Vergence"). Abattis has teamed up with respected naturopathic doctor and nutraceuticals product developer Dr. Brazos Minshew to launch Comfort, a breakthrough nutraceutical combining traditional herbal remedies to safely and effectively address occasional pain. Released on Cyber Monday and set for introduction into the US and Canada in December 2018, the Comfort product is 100% owned by Vergence, and will be marketed under the newly-formed health and wellness brand.
Vancouver, British Columbia--(Newsfile Corp. - December 14, 2018) - CEO & President of Abattis Bioceuticals Corp., Robert Abenante, speaks on the medical marijuana company's many facets including: a vape line, extraction and laboratory services.If you cannot view the video above, please visit:https://www.b-tv.com/abattis-bioceuticals-ceo-clip-90sec/Abattis Bioceuticals Corp. is being featured on BNN Bloomberg on Dec. 15 - Dec. 16, 2018, throughout the day and evenings.Abattis Bioceuticals (CSE: ATT) (OCTQB: ATTBF)abattis.comAbout CEO Clips:CEO Clips is the largest library ...
Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide an update on the recent soft-launch of its cannabinoid-infused nutraceutical Comfort (“Comfort”) through the Company’s wholly-owned subsidiary, Vergence Naturals (“Vergence”), on Cyber-Monday, November 26, 2018. Canada One Communications Inc. (“Canada One”), an Abattis media partner, quotes WorkArea.com in selecting Monday as the best day for e-commerce site sales.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that the Company will be displaying a booth at the O’Cannabiz Conference and Expo taking place at Parq Casino in Vancouver, BC on December 10-11th, 2018 (“O’Cannabiz”). O’Cannabiz will address key cannabis investment themes, emerging opportunities in the developing Canadian market, as well as significant trends and developments in the cannabis industry, from consumers to businesses. The conference will display over 100 global and local cannabis professionals, offering attendees and investors up to date information on what’s next for Canada’s growing cannabis industry.
Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has signed a non-binding letter of intent dated December 6, 2018 (the “LOI”) to acquire 100% interest in NutriVida Corp. (“NutriVida”) through an arm’s length transaction, a privately held fertilizer and nutrient company located in Langley, BC. The acquisition of Nurtivida plays directly into the Company’s push to add to its current and future cannabis growth assets, including, but not limited to, its acquisition of Gabriola Green Farms Inc. earlier in 2018. Specifically, the management of NutriVida has been a prominent force in the fertilizer and cultivation industry, with over 35 years of experience and, providing a vast wealth of knowledge and experience in researching, innovating, manufacturing, and selling all-natural, bio-safe, fertilizers and plant nutrients.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) comments on the news release regarding the British Columbia Securities Commission (“BCSC”) Temporary Order dated November 26, 2018. The BCSC issued a temporary order on Monday, November 26, 2018, which centers around share issuances by 11 CSE issuers to a very large group of consultants between February, 2018, and August, 2018. Abattis has been named as 1 of the 11 issuers as they have ongoing consulting agreements with certain members listed in the group of respondents (the “Respondents”) for services ranging from accounting and finance to marketing. Also, certain of the Respondents participated in an Abattis private placement for $2.25M. For these reasons, Abattis has been named as an issuer in this temporary order.
Abattis Bioceuticals Corp (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that the Company has signed a Distribution Agreement (the "Distribution Agreement") with Shefield & Sons Tobacconists Inc. ("Shefield & Sons") to sell the Abattis vaporizer line in all Shefield & Sons stores across Canada. Shefield & Sons has been in business since 1976 and is one of Canada's pre-eminent tobacconist franchisors with locations in major cities across Canada.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce the release of its first proprietary product, Comfort, through the Company’s wholly-owned subsidiary Vergence Naturals (“Vergence”). Comfort, a brand-new proprietary nutraceutical, which contains Alpinia Galangal and Capsicum Annuum, was developed by Abattis’ research scientists to activate the endocannabinoid system (“ECS”) and nourish endorphin release in response to pain. Comfort Extra Strength, the second addition to the Comfort product line, is set to be released to the public in mid-January 2019 and will be enhanced with hemp-based phytocannabinoids, with a specific focus on cannabidiol (CBD).
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) to acquire 100% of Select Strains Inc. (“Select Strains”). Select Strains has almost two decades of experience within the cannabis space, specifically within the fields of cannabis testing, research, cultivation and optimization of proprietary seeds and strains. With a portfolio of over 140 laboratory-tested craft cannabis strains, Select Strains will allow for the continued differentiation of the Abattis brand, leveraging unique craft strains in an increasingly generic, highly competitive and standardised cannabis market.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce the appointment of Ingredient Identity LLC (“Ingredient Identity”), a Canadian and US regulatory and compliance agency, to assist the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. (“Vergence Naturals”), with their ongoing Canadian and US regulatory compliance program. “Regulatory compliance is a cornerstone objective for Vergence Naturals, or any nutraceutical business,” stated Rob Abenante, President and CEO of Vergence Naturals.
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering the launch of Abattis Bioceuticals Corp.'s (ATT.CN) (ATTBF) latest product innovation. “Comfort”, a nutraceutical designed to alleviate chronic pain and inflammation, is the first in line of a dozen new products the company expects to launch over 36 months. According to a recent Institute of Medicine Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, stated, “Acute or chronic pain is a significant public health problem that costs society at least $560-$635 billion annually in North America alone.
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2018) - Abattis Bioceuticals Corp. (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") is pleased to announce the additions of Kent McParland and Cedric Wilson to the Board of Directors (the "Board"). Mr. McParland and Mr. Wilson replace Cameron Paddock and Rene David who have left Abattis to concentrate on other ventures. Mr. McParland is a Chartered Professional Accountant experienced in multiple industries and geographical locations. ...